These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 33291616)

  • 1. Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy.
    Venkatraman S; Meller J; Hongeng S; Tohtong R; Chutipongtanate S
    Vaccines (Basel); 2020 Dec; 8(4):. PubMed ID: 33291616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic interventions combined with CTLA-4 and PD-1/PD-L1 blockade for the treatment of tumors: mechanisms and strategies.
    Liao L; Xu H; Zhao Y; Zheng X
    Front Med; 2023 Oct; 17(5):805-822. PubMed ID: 37897562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of tumor microenvironment in the regulation of PD-L1: A novel role in resistance to cancer immunotherapy.
    Kalantari Khandani N; Ghahremanloo A; Hashemy SI
    J Cell Physiol; 2020 Oct; 235(10):6496-6506. PubMed ID: 32239707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
    Borcherding N; Kolb R; Gullicksrud J; Vikas P; Zhu Y; Zhang W
    J Mol Biol; 2018 Jul; 430(14):2014-2029. PubMed ID: 29800567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer.
    Kok VC
    Front Oncol; 2020; 10():268. PubMed ID: 32185135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoints and cancer development: Therapeutic implications and future directions.
    Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
    Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy.
    Lee J; Kim EH
    Front Oncol; 2023; 13():1233376. PubMed ID: 37614504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.
    Yadav R; Hakobyan N; Wang JC
    Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
    Ma W; Gilligan BM; Yuan J; Li T
    J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AP-1 Transcription Factors as Regulators of Immune Responses in Cancer.
    Atsaves V; Leventaki V; Rassidakis GZ; Claret FX
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31340499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune checkpoint blockade for hematologic malignancies: a review.
    Pianko MJ; Liu Y; Bagchi S; Lesokhin AM
    Stem Cell Investig; 2017; 4():32. PubMed ID: 28529947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitors: recent progress and potential biomarkers.
    Darvin P; Toor SM; Sasidharan Nair V; Elkord E
    Exp Mol Med; 2018 Dec; 50(12):1-11. PubMed ID: 30546008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.
    Xiao Q; Nobre A; Piñeiro P; Berciano-Guerrero MÁ; Alba E; Cobo M; Lauschke VM; Barragán I
    J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31968651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.
    Yang M; Lin C; Wang Y; Chen K; Zhang H; Li W
    Genome Med; 2022 Jul; 14(1):72. PubMed ID: 35799269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy.
    Liu J; Liu Q; Zhang X; Cui M; Li T; Zhang Y; Liao Q
    Cancer Cell Int; 2021 Feb; 21(1):137. PubMed ID: 33637086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
    Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
    Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.
    Zabeti Touchaei A; Vahidi S
    Cancer Cell Int; 2024 Mar; 24(1):102. PubMed ID: 38462628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.